Theravance Biopharma
(NASDAQ) TBPH
Theravance Biopharma Financials at a Glance
Market Cap
$881.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$109.78M
Net Income (TTM)
$114.54M
EPS (TTM)
$2.20
P/E Ratio
7.71
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Price
$16.98
Volume
439,915.625
Open
$17.00
Price
$16.98
Volume
439,915.625
Open
$17.00
Previous Close
$16.98
Daily Range
$16.98 - $17.04
52-Week Range
$10.82 - $21.03
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
0.62 (Low)
Price
$16.98
Volume
439,915.625
Open
$17.00
Previous Close
$16.98
Daily Range
$16.98 - $17.04
52-Week Range
$10.82 - $21.03
Estimated Earnings Date
Aug 11, 2026
TBPH News
TBPH: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Theravance Biopharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
90
CEO
Rick E. Winningham, MBA
Website
www.theravance.comHeadquarters
South San Francisco, CA 94080, US
TBPH Financials
Key Financial Metrics (TTM)
Gross Margin
80.37%
Operating Margin
0.08%
Net Income Margin
104.34%
Return on Equity
43.85%
Return on Capital
-3.56%
Return on Assets
24.25%
Earnings Yield
12.97%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$881.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
51.83M
Volume
439.92K
Avg. Volume
530.89K
Financials (TTM)
Gross Profit
$88.23M
Operating Income
$88.00K
EBITDA
$142.50M
Operating Cash Flow
$268.78M
Capital Expenditure
-$42.00K
Free Cash Flow
$268.74M
Cash & ST Invst.
$394.67M
Total Debt
$73.30M
Theravance Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$17.70M
+15.0%
Gross Profit
$16.26M
+313.2%
Gross Margin
91.88%
N/A
Market Cap
$881.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$9.79M
N/A
Employees
90
N/A
Net Income
-$4.93M
+63.7%
EBITDA
-$5.03M
+61.5%
Quarterly Fundamentals
Total Cash
$394.67M
+201.6%
Total Debt
$73.30M
+52.2%
Accounts Receivable
$15.58M
+1.5%
Inventory
$0.00
N/A
Long Term Debt
$62.55M
+67.5%
Short Term Debt
$10.75M
-0.5%
Return on Assets
24.25%
N/A
Return on Invested Capital
0.02%
N/A
Free Cash Flow
$73.28M
+70.3%
Operating Cash Flow
$73.28M
+70.3%